These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3461882)

  • 1. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
    Donehower RC; Karp JE; Burke PJ
    Cancer Treat Rep; 1986 Sep; 70(9):1059-65. PubMed ID: 3461882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W; Nowak B; Keating MJ
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
    Stone RM; Spriggs DR; Dhawan RK; Arthur KA; Mayer RJ; Kufe DW
    Leukemia; 1990 Dec; 4(12):843-7. PubMed ID: 2243507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
    Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia.
    Ochs J; Sinkule JA; Danks MK; Look AT; Bowman WP; Rivera G
    J Clin Oncol; 1984 Oct; 2(10):1092-7. PubMed ID: 6593435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.
    Capizzi RL; White JC; Powell BL; Perrino F
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):54-69. PubMed ID: 1780754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.
    Pommier Y; Pochat L; Marie JP; Zittoun RA
    Cancer Treat Rep; 1983 Apr; 67(4):371-3. PubMed ID: 6850654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute leukemia with amsacrine and high-dose cytarabine.
    Arlin ZA; Gaddipati J; Ahmed T; Mittelman A; Friedland M; Rieber E
    Cancer Treat Rep; 1985 Sep; 69(9):1001-2. PubMed ID: 3839713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy.
    Atkins JN; Muss HB; Capizzi RL; Cooper MR; Craig J; Cruz JM; Jackson DV; Powell B; Richards F; Spurr CL
    Cancer Treat Rep; 1985; 69(7-8):897-9. PubMed ID: 4040427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of cytarabine and hydroxyurea.
    Pfeifle CE; Howell SB
    Cancer Treat Rep; 1983 Dec; 67(12):1127-9. PubMed ID: 6652629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.